omniture
天境生物科技(上海)有限公司 IMab

Latest News

I-Mab Reports Full Year 2023 Financial Results and Business Update

* Recently announced agreement to divest assets and business operations in China marks an importa...

2024-03-15 05:00 2892

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

* Agreement marks an important milestone to advance the Company's intent to become a U.S.-based b...

2024-02-07 19:00 1204

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company...

2023-11-06 21:00 1059

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

* FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data...

2023-11-02 20:00 822

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Co...

2023-11-01 20:00 1153

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Compan...

2023-10-16 20:00 1269

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

-        Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete...

2023-10-10 20:00 1145

I-Mab Announces Upcoming Participation at September Conferences

ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is...

2023-09-05 20:00 1172

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

* Significant progress made year-to-date on key clinical assets: ‐         Uliledlimab (CD73 antib...

2023-08-17 18:00 4074

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a c...

2023-08-08 20:00 1459

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2023-07-05 20:00 1650

I-Mab Announces the Appointment of Raj Kannan as CEO

GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nas...

2023-06-22 20:00 2209

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

-  Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger...

2023-05-26 05:01 2056

I-MAB Filed 2022 Annual Report on Form 20-F

GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasda...

2023-05-01 20:00 1907

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2023-04-26 21:16 2673

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

* Award is an important victory for I-Mab and its shareholders on multiple levels, ending the mul...

2023-04-25 13:46 1590

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2023-04-24 21:00 1688

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

* Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overal...

2023-03-31 18:30 4109

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

GAITHERSBURG, Md. and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq...

2023-03-20 20:00 1804

MSCI ESG Updated I-Mab to "A" Rating

GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2023-03-07 21:02 1572
12345 ... 7